Background: Since the end of the 1980s, the magnitude of survival prolongation or mortality reduction has not
INTRODUCTION
Between 2002 and 2006 in Canada, 2252 new cases of cancer occurred in adolescents and young adults (ayas) 1 , accounting for about 2% of all newly diagnosed invasive cancers [2] [3] [4] .
Unfortunately, since the late 1980s, the magnitude of survival prolongation or mortality reduction has not been the same for ayas with cancer as for their older and younger counterparts 1, 2, 5 . Precise reasons for the failure to improve survival in this cohort are unknown, but several factors that can be broadly categorized in terms of the patient, the health care system, and the disease and its treatment have been suggested. In terms of the patient, ayas generally do not seek medical help and do not consider cancer when experiencing nonspecific symptoms [6] [7] [8] [9] . Many ayas do not have access to a family physician-either because of limited availability (Canada) or a lack of insurance (the United States) 10 -making it less likely that they will be referred to a specialist. In terms of the health care system, health professionals often underestimate symptoms of cancer in younger age groups 9, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Wait times for specialized tests are long in the public sector, and access to specialized medical expertise is limited for ayas. In terms of the disease and its treatment, distinct tumour biology, lack of participation by ayas in clinical trials (because of a lack of trials for ayas, failure to inform ayas about available trials, or an inability or reluctance of ayas to participate in trials) [6] [7] [8] [9] , and financial limitations on the part of both the patient and the family or care provider can underlie the lack of progress within this patient population. Taken together, the foregoing factors (although they have not been systematically explored) are thought to result in delays in diagnosis, lack of access to appropriate treatments, and ultimately poorer survival.
In 2003, we developed the first Canadian multidisciplinary aya oncology clinic at the Jewish General Hospital (affiliated with McGill University, Montreal, QC) to better serve this unique patient population. The aim of the present analysis was to quantify 3 types of treatment delay in the aya population (patient delay, health care system delay, and treatment delay) and to identify factors contributing to those delays so as to better predict their prognostic effects. Specifically, an association of longer delays with poorer survival or more advanced disease was hypothesized to explain poorer survival rates in the aya population.
METHODS

Study Design and Data Collection
In a retrospective chart review of 110 ayas (18-49 years of age) treated for cancer at the Jewish General Hospital during 2010-2011, relevant data related to treatment delays, treatment efficacy, and obstacles to treatment were extracted. A detailed medical history, including timelines for the appearance of symptoms, first appointment with the family doctor and oncologist, date of diagnosis, and participation in clinical trials had been elicited from each patient at the time of first presentation to the aya clinic. Additional information was gathered from medical charts. Data about sociodemographic parameters such as sex, age, ethnicity, primary residence, marital status, education level, household income, medical insurance, family cancer history, and current life style (Table i) were also collected. French or English versions of the relevant questionnaires (Table ii) were provided based on patient preference. Clarification or assistance was provided to patients as needed.
Ethics
Ethics approval for the questionnaires was obtained from the Research Ethics Committee of the Jewish General Hospital. The data were analyzed anonymously.
Statistics
The interval between discovery of symptoms and the time at which the patient was diagnosed and received therapy was divided roughly into patient delay, health care system delay, and treatment delay. "Patient delay" was defined as the time elapsed from the initial discovery of symptoms to first contact with a medical provider. "Health care system delay" was defined as the interval from the first provider consultation until the diagnosis was made. "Treatment delay" was defined as the interval between diagnostic tests and the wait time before initiation of treatment.
Relations between the delays and overall survival (the time from cancer diagnosis to death from any cause) were considered by comparing overall survival for each type of delay. Statistical analyses were performed using Stata 12 (StataCorp LP, College Station, TX, U.S.A.). Descriptive statistics consist of proportions for categorical variables and means or medians for continuous variables such as age and delays. Mann-Whitney-Wilcoxon nonparametric tests were used for groups with only two categories. Associations between continuous variables were tested using the Spearman rank correlation. Because of the exploratory nature of this study, a p value of 0.05 was chosen as the significance level, and no adjustment was made for multiple comparisons.
RESULTS
Patient Population
Mean age at diagnosis was 30 years. The major ethnicity group (white) accounted for 75% of the patients. In our cohort, 15% had completed high school; 20%, college; 34%, a university degree; and 15%, postgraduate training. Annual income was less than $50,000 for 28% of the sample, and more than $50,000 for 40% ( Table i) .
Patient reports about their first health care contact fell broadly into 5 categories: 32% had been seen by a public general practitioner, 8% by a private general practitioner, 22% by another specialist or a walk-in clinic, and 24% in an emergency room. The most common cancers were central nervous system tumours (n = 33, 30%). Others included gastrointestinal cancer (n = 20, 18.2%), sarcoma (n = 16, 14.5%), germ-cell tumour (n = 14, 12.7%), breast cancer (n = 13, 11.8%), lymphoma (n = 5, 4.5%), melanoma (n = 4, 3.6%), head-and-neck cancer (n = 3, 2.7%), lung and renal cancers (n = 1 each, 0.9%; Table i ). Figure 1 presents the distribution of delays for each patient. The median overall delay (that is, the sum of the patient, health care system, and treatment delays) was 173 days [interquartile range (iqr): 68-410 days]. The median patient delay was 22 days (iqr: 1-214 days). The median health care system delay was 56 days (iqr: 12-174 days), and the median treatment delay was 32 days (iqr: 0-72 days). Table iii summarizes the results.
Delay Analyses
Analyses of Factors Possibly Contributing to Delay
Compared with male patients, female patients experienced significantly longer patient delay (p = 0.001, Table iii ). Age at diagnosis and ethnicity were positively correlated with patient delay (r = 0.390, p < 0.001 and p = 0.041 respectively; Table iii ). However, a trend toward an inverse correlation of age with treatment delay was observed (p = 0.087, Table iii) . Delays were shorter when the patient's first medical contact was with an emergency room or a private general practitioner (p = 0.004 compared with patients having other types of initial health care contact). Of brain cancer patients, 52% went directly to the emergency room; of patients with other cancer types, 16% opted for an emergency room visit (p < 0.001). Patients with brain and spinal cancer experienced a significantly longer treatment delay (p = 0.001 compared with patients having other types of cancer, Table iii) . We observed no association of treatment delay with sex and health care contact (p = 0.988, Table iii).
Survival Analysis
The daily death rate for our sample was estimated at 2463×10 -4 , equivalent to a 9% annual mortality rate. Median survival for the cohort overall was 3.76 years. No variable except emergency room presentation was significantly associated with survival (Table iv) . And although there was an association between first health care contact and cancer type, patients with a specific type of cancer were not significantly more likely to die (p = 0.807, Table iv).
DISCUSSION
In this study, we tried to quantify cancer diagnosis delays and to uncover any association of those delays with survival.
Although our work was conducted within the framework of issues specific to ayas, the same approach could be used to address concerns within and across disease sites and age ranges.
We found that the total delay from presentation to treatment at our institution was almost 6 months for patients treated at the aya oncology clinic. The period from first health care contact to diagnosis was the greatest contributor to the total delay, which is consistent with other reports 3 . Interestingly, we found a very mild positive correlation of age with patient delay, suggesting that older onset to diagnosis and treatment for aya patients and olderadult patients with brain tumours presenting at the McGill University aya Oncology Centre of the Jewish General Hospital from 1 July 2010 to 22 December 2011. They found that the total delay and the treatment delay were longer for the aya patients than for the older-adult patients (p = 0.013 and p = 0.048 respectively).
CONCLUSIONS
Despite limitations to our study (including measurement bias related to the analysis of retrospective data obtained from questionnaires completed for clinical purposes and from medical charts; a small sample size; and collection of data from a single institution in Canada), we quantified delays in diagnosis and treatment for ayas with cancer. We found that the median overall delay was 173 days from first symptoms to treatment, of which health care system delay accounted for a median of 56 days' delay. Our analysis is important because it begins to emphasize that delays for ayas with cancer have been associated with more advanced presentation, a need for more therapy, and a likelihood of worse outcomes. The lengthy observed delay could be shortened with some changes to health care policy. We also noticed a clear disparity in clinical trial participation. A large proportion of our patients were not aware of clinical trials, emphasizing a need for greater promotion and advertisement of such trials. 
